Literature DB >> 3427402

The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study.

I E Ormerod1, D H Miller, W I McDonald, E P du Boulay, P Rudge, B E Kendall, I F Moseley, G Johnson, P S Tofts, A M Halliday.   

Abstract

The form and distribution of MRI abnormalities in 114 patients with clinically definite multiple sclerosis (MS) have been compared with observations on 53 apparently healthy individuals, 129 patients with isolated focal neurological lesions with which MS often presents (51 patients with optic neuritis, 44 with isolated brainstem lesions and 34 with isolated spinal cord syndromes) and 105 patients with disorders which may be confused clinically or radiologically with MS. The latter comprised 55 patients with cerebral vascular disease (including 7 cases of dementia with diffuse white matter disease), 24 with degenerative ataxic disorders, 8 with cerebellar tonsillar ectopia, 7 with sarcoidosis and 11 with a variety of other disorders. Periventricular abnormalities were found in all but 2 patients with MS and discrete white matter lesions in all but 12. Characteristically the periventricular changes in MS were irregular in outline. Periventricular abnormalities which were often milder and of smooth outline were seen in 37/55 patients with cerebral vascular disease, 9/24 with cerebellar degeneration, 5/7 with sarcoidosis and in 2/3 apparently healthy individuals over the age of 60. The appearances in the 7 cases of dementia resembled those with advanced MS. Cerebellar and/or brainstem atrophy characteristic of the cerebellar degenerations, in the absence of white matter abnormalities, was helpful in making the distinction from MS. Congenital anomalies and tumours in the region of the brainstem and foramen magnum were readily shown. More than half the patients with symptoms attributable to isolated focal neurological lesions had additional lesions at presentation. MS cannot be diagnosed in these cases at presentation, but repeat scans after 5 to 20 months in 25 patients with optic neuritis and 10 with clinically isolated brainstem lesions have shown new lesions in 7 (20%). The patients with new lesions fulfil the criteria for clinically probable MS (Poser et al., 1983). Measurements of T1 and T2 in vivo permitted the distinction of acute from chronic brainstem lesions. There were quantitative differences in T1 and T2 between the normal appearing white matter in MS and normal brain. Studies of postmortem brains provided convincing evidence that the MRI abnormalities in MS correspond with plaques. Evidence is adduced to support the view that an important source of the abnormal NMR signals in acute lesions is oedema, and in chronic lesions is gliosis; demyelination per se is unlikely to make an important contribution.

Entities:  

Mesh:

Year:  1987        PMID: 3427402     DOI: 10.1093/brain/110.6.1579

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  115 in total

Review 1.  Physicians, subsequence and consequence.

Authors:  W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis.

Authors:  M Tintoré; A Rovira; M J Martínez; J Rio; P Díaz-Villoslada; L Brieva; C Borrás; E Grivé; J Capellades; X Montalban
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

3.  Making the diagnosis of multiple sclerosis.

Authors:  J Palace
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

4.  Towards quantitative measurements of relaxation times and other parameters in the brain.

Authors:  P S Tofts; E P du Boulay
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

Review 5.  MR imaging of midbrain pathologies.

Authors:  E Hattingen; S Blasel; M Nichtweiss; F E Zanella; S Weidauer
Journal:  Clin Neuroradiol       Date:  2010-06-09       Impact factor: 3.649

6.  Destructive lesions in demyelinating disease.

Authors:  B D Youl; A G Kermode; A J Thompson; T Révész; F Scaravilli; R O Barnard; F J Kirkham; B E Kendall; D Kingsley; I F Moseley
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

Review 7.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

8.  A multiparametric evaluation of regional brain damage in patients with primary progressive multiple sclerosis.

Authors:  Antonia Ceccarelli; Maria A Rocca; Paola Valsasina; Mariaemma Rodegher; Elisabetta Pagani; Andrea Falini; Giancarlo Comi; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2009-09       Impact factor: 5.038

9.  MRI in the investigation of patients with myelopathy thought to be due to multiple sclerosis.

Authors:  A Papadopoulos; A Gouliamos; S Trakadas; A Kalovidouris; P Sgouropoulos; S Gatzonis; L Vlahos
Journal:  Neuroradiology       Date:  1995-07       Impact factor: 2.804

10.  Correlation between spinal cord MRI and clinical features in patients with demyelinating disease.

Authors:  A Papadopoulos; S Gatzonis; A Gouliamos; S Trakadas; A Kalovidouris; P Sgouropoulos; L Vlachos; C Papavasiliou
Journal:  Neuroradiology       Date:  1994       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.